MMMichelle Victoria Malz

Michelle Victoria Malz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle Victoria Malz has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Marc Freichel

    Institute of Pharmacology, Heidelberg University, Heidelberg, Germany

    2 shared publications
  • Roger Ottenheijm

    Institute of Pharmacology, Heidelberg University, Heidelberg, Germany

    2 shared publications
  • Andreas H. Guse

    Calcium Signalling Group, Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

    1 shared publication
  • Constanze Schmidt

    Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg Heidelberg, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg Heidelberg Germany

    1 shared publication
  • Felix Wiedmann

    Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg Heidelberg, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg Heidelberg Germany

    1 shared publication
  • Jan David Lanzer

    Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany

    1 shared publication

Latest Publications

  • Open Access

    JPT2/HN1L functions as an NAADP-binding protein in a cell-type-specific manner

    by Roger Ottenheijm, Kai Winterberg, Vivien Throm, Michelle Malz, Merima Bukva, Volodymyr Tsvilovskyy, Rebekka Medert, Andreas H. Guse, Marc Freichel

    Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger evoking Ca 2+ release from intracellular Ca 2+ stores by targeting several Ca 2+ channels, including two-pore channels (TPC1/2), transient receptor potential mucolipin-1 (TRPML1), or ryanodine receptor type 1 (RYR1). For activation of Ca 2+ channels, NAADP requires binding proteins, such as JPT2/HN1L and LSM12. So far, their function has been analyzed in several cell lines and only a very limited number of primary cells; however, their physiological relevance in cell types known to utilize NAADP signaling remains unclear. Here, we generated Jpt2/Hn1l –/– mice to evaluate the contribution of JPT2/HN1L proteins to platelet aggregation and Ca 2+ signaling in cardiomyocytes, mast cells, and T cells. NAADP is known to contribute to collagen-related peptide (CRP-XL)- evoked platelet aggregation, but this was not altered by JPT2/HN1L deletion. Functional Ca 2+ imaging revealed that JPT2/HN1L plays a strikingly cell-type specific role in NAADP-mediated Ca 2+ release. In electrically paced ventricular cardiomyocytes, β-adrenergic stimulation is known to evoke arrhythmogenic spontaneous diastolic Ca 2+ transients, which were not altered in their frequency in Jpt2/Hn1l –/– myocytes. Further, antigen-evoked Ca 2+ transients in peritoneal mast cells (PMCs) are not changed in Jpt2/Hn1l –/– PMCs. However, CD4 + T cells displayed a pronounced requirement for JPT2/HN1L. Following T cell receptor/CD3 stimulation, global Ca 2+ elevations and early NAADP-driven Ca 2+ microdomains, which occur within tens of milliseconds of TCR/CD3 engagement and serve as initiating signals for downstream immune activation, were significantly decreased in Jpt2/Hn1l –/– CD4 + cells. We conclude that JPT2/HN1L is indispensable for NAADP-mediated Ca 2+ release in T cells, but dispensable in cardiomyocytes, platelets, and mast cells, at least for the agonists employed. Accordingly, LSM12 might compensate for the loss of JPT2/HN1L. Together, JPT2/HN1L is not universally required as an NAADP-binding protein but exhibits cell-type specificity, with an essential function in T cell Ca 2+ signaling.

  • Open Access

    The Transcriptional Landscape of Atrial Fibrillation: A Systematic Review and Meta-analysis

    by Sergio Alejandro Gómez-Ochoa, Malte Möhn, Michelle Victoria Malz, Roger Ottenheijm, Jan D. Lanzer, Felix Wiedmann, Manuel Kraft, Taulant Muka, Constanze Schmidt, Marc Freichel, et al.

    Background and Aims Despite advances in understanding atrial fibrillation (AF) pathophysiology through the lens of transcriptomics, marked differences in the key AF genes between studies remain, while drugs targeting preserved dysregulated pathways are limited. This systematic review and meta-analysis aimed to provide a consensus transcriptional signature of AF and use it to identify potentially repurposable drugs. Methods Bibliographic databases and data repositories were systematically searched for studies reporting gene expression patterns in atrial heart auricle tissue from patients with AF and controls in sinus rhythm. A qualitative synthesis and a transcriptomics meta-analysis were performed. We calculated the pooled differences in individual gene expression to create a consensus signature (CS), from which we identified differentially regulated pathways and estimated transcription factors activity. We also created a protein-protein interaction network to identify drug interactions with highly interconnected genes (hub genes) from the AF-CS. Results Thirty-four observational studies were assessed in the qualitative synthesis, while fourteen, comprising 511 samples (338 AF and 173 SR), were included in the meta-analysis. Despite the heterogeneity observed across individual studies, the AF-CS in both chambers were consistent and robust, showing a better performance in classifying AF status than individual studies. The functional analysis revealed commonality in the dysregulated cellular processes across the atria, including extracellular matrix remodeling, downregulation of cardiac conduction pathways, metabolic derangements, and innate immune system activity processes. Finally, drug-gene analyses highlighted several compounds as repurposing drug candidates for AF, highlighting lipid-lowering agents, antioxidants, and retinoids, among others. Conclusions Despite variability in individual studies, this meta-analysis elucidated conserved molecular pathways involved in AF pathophysiology across its phenotypes, offering robust and potentially generalizable diagnostic biomarkers. From this AF-CS, we identified potential compounds targeting these dysregulated pathways, thereby addressing an extant gap in AF-specific pharmacotherapy. Key Question Can a meta-analytically derived consensus transcriptional signature effectively capture the core molecular mechanisms underlying AF and serve as a basis for identifying novel drug candidates targeting these conserved pathways? Key Findings Extracellular matrix remodeling, downregulation of cardiac conduction pathways, and modulation of innate immune system activity emerged as conserved molecular hallmarks across the AF spectrum. Drug-gene interaction analyses highlighted the repurposing potential of lipid-lowering agents, antioxidants, and retinoids, among other compounds, for targeted intervention in these dysregulated pathways. Take Home Message Despite AF’s complexity, a transcriptional signature derived through a meta-analysis can pinpoint conserved molecular pathways across AF phenotypes. These insights provide a foundation for identifying and repurposing drugs targeting the core dysregulated processes in the disease, offering new avenues for targeted, mechanism-based treatment of AF.